DelveInsight’s, “Diabetic Peripheral Neuropathy Pipeline Insight 2024” report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Diabetic Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our comprehensive Diabetic Peripheral Neuropathy Pipeline Report to stay informed about the latest advancements. Download copy now @ Diabetic Peripheral Neuropathy Pipeline Outlook

 

Key Takeaways from the Diabetic Peripheral Neuropathy Pipeline Report

• In September 2024:- Eli Lilly and Company- The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
• In September 2024:- GlaxoSmithKline- A Multicenter Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Target Engagement of GSK3858279 in Adult Participants With Chronic Diabetic Peripheral Neuropathic Pain (DPNP) /NEPTUNE-17.
• In September 2024:- Boston Scientific Corporation- The purpose of the study is to evaluate the effects of stimulation parameters on clinical outcomes of Spinal Cord Stimulation (SCS) in the treatment of chronic, intractable limb pain resulting from painful Diabetic Peripheral Neuropathy (pDPN).
• DelveInsight’s Diabetic Peripheral Neuropathy pipeline report depicts a robust space with 10+ active players working to develop 15+ pipeline therapies for Diabetic Peripheral Neuropathy treatment.
• The leading Diabetic Peripheral Neuropathy Companies such as Helixmith Co., Ltd., WinSanTor, Inc., Lexicon Pharmaceuticals, Inc, Vertex Pharmaceuticals Incorporated, Biogen, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, Apurano Pharmaceuticals GmbH, and others.
• Promising Diabetic Peripheral Neuropathy Therapies such as VM202, WST-057, LX9211, and others.

 

Dive into our Diabetic Peripheral Neuropathy Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Diabetic Peripheral Neuropathy Treatment Therapies

 

Diabetic Peripheral Neuropathy Emerging Drugs Profile

• VM202: Helixmith Co., Ltd.

VM202 (Engensis) is an innovative gene therapy drug that provides fundamental treatment through tissue regeneration. Engensis it is non-viral plasmid DNA product, and is designed to express recombinant HGF protein in nerve and Schwann cells to promote nerve system regeneration and induce the formation of microvascular blood vessels. Engensis (VM202) has the potential to reverse the underlying cause of neuropathy through an angio-neurorestorative effect, not simply managing the pain. US FDA granted RMAT (Regenerative Medicine Advanced Therapy) designation to VM202-DPN in 2018. This is first time in Korea, and the first and the only RMAT designation worldwide in pain area. Engensis is the first RMAT designated therapy in US of common diseases with over millions of patients. Engensis has been attracting huge attention in Painful DPN because of its big market size. Currently, the drug is in Phase III stage of its development for the treatment of Diabetic peripheral neuropathy.

• WST-057: WinSanTor, Inc.

WST-057 is a novel investigational drug candidate that has been in development for over ten years. THE aim of the company is to develop the first disease-modifying treatment for peripheral neuropathy that has the potential to prevent and reverse the nerve damage and the symptoms associated with the disease. WST-057, showed the ability to prevent nerve damage and regrow damaged nerves. Phase I and Phase II are now complete. Topical WST-057 was shown to be safe and tolerable when administered to diabetic peripheral neuropathy patients for up to six months in these studies, but will need to be studied in a larger population. WST-057 has received FastTrack designation. Currently, the drug is in Phase III stage of its development for the treatment of Diabetic peripheral neuropathy.

• LX9211: Lexicon Pharmaceuticals, Inc

LX9211 is an orally-delivered small molecule compound Lexicon is developing as a treatment for diabetic peripheral neuropathic pain. The scientists identified the target of LX9211, adapter-associated kinase 1, or AAK1, in our target discovery efforts based on their discovery that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain in preclinical models. LX9211 is discovered within drug discovery alliance with Bristol-Myers Squibb from which Lexicon Pharmaceuticals, Inc hold exclusive development and commercialization rights. Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways. LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain. Currently, the drug is in Phase II stage of its development for the treatment of Diabetic peripheral neuropathy.

 

Download the Diabetic Peripheral Neuropathy Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Diabetic Peripheral Neuropathy Clinical Trials Assessment

 

Diabetic Peripheral Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Diabetic Peripheral Neuropathy Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Dive into our detailed Diabetic Peripheral Neuropathy Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Diabetic Peripheral Neuropathy Products, Companies, and Unmet Needs

 

Scope of the Diabetic Peripheral Neuropathy Pipeline Report

• Coverage- Global
• Diabetic Peripheral Neuropathy Companies- Helixmith Co., Ltd., WinSanTor, Inc., Lexicon Pharmaceuticals, Inc, Vertex Pharmaceuticals Incorporated, Biogen, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, Apurano Pharmaceuticals GmbH, and others.
• Diabetic Peripheral Neuropathy Therapies- VM202, WST-057, LX9211, and others.
• Diabetic Peripheral Neuropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diabetic Peripheral Neuropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Gain valuable insights into emerging therapies and innovations with our Diabetic Peripheral Neuropathy Pipeline Report @ Diabetic Peripheral Neuropathy Market Drivers and Barriers, Future Perspectives and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Diabetic Peripheral Neuropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetic Peripheral Neuropathy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. VM202: Helixmith Co., Ltd.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. LX9211: Lexicon Pharmaceuticals, Inc
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Diabetic Peripheral Neuropathy Key Companies
21. Diabetic Peripheral Neuropathy Key Products
22. Diabetic Peripheral Neuropathy- Unmet Needs
23. Diabetic Peripheral Neuropathy- Market Drivers and Barriers
24. Diabetic Peripheral Neuropathy- Future Perspectives and Conclusion
25. Diabetic Peripheral Neuropathy Analyst Views
26. Diabetic Peripheral Neuropathy Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/